With 2.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.38 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $585.5 whereas the lowest price it dropped to was $573.0. The 52-week range on ISRG shows that it touched its highest point at $584.60 and its lowest point at $355.17 during that stretch. It currently has a 1-year price target of $586.18. Beta for the stock currently stands at 1.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ISRG was up-trending over the past week, with a rise of 7.36%, but this was up by 8.25% over a month. Three-month performance surged to 22.07% while six-month performance rose 37.03%. The stock gained 61.20% in the past year, while it has gained 11.90% so far this year. A look at the trailing 12-month EPS for ISRG yields 6.22 with Next year EPS estimates of 7.88. For the next quarter, that number is 1.77. This implies an EPS growth rate of 20.54% for this year and 14.51% for next year. EPS is expected to grow by 16.14% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 9.71%.
Float and Shares Shorts:
At present, 356.20 million ISRG shares are outstanding with a float of 353.98 million shares on hand for trading. On 2024-12-31, short shares totaled 4.4 million, which was 123.00000499999999 higher than short shares on 1732838400. In addition to Dr. Gary S. Guthart Ph.D. as the firm’s CEO & Director, Mr. David J. Rosa serves as its President & Director.
Institutional Ownership:
Through their ownership of 0.89281 of ISRG’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ISRG reported revenue of $2038100000.0 and operating income of $577300000.0. The EBITDA in the recently reported quarter was $693500000.0 and diluted EPS was $1.56.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ISRG since 17 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ISRG analysts setting a high price target of 700.0 and a low target of 265.0, the average target price over the next 12 months is 573.2232. Based on these targets, ISRG could surge 19.85% to reach the target high and fall by -54.63% to reach the target low. Reaching the average price target will result in a decline of -1.86% from current levels.
Analysts have provided yearly estimates in a range of $6.9657 being high and $6.79581 being low. For ISRG, this leads to a yearly average estimate of $6.87576. Based on analyst estimates, the high estimate for the next quarter is $1.83 and the low estimate is $1.72. The average estimate for the next quarter is thus $1.78.
